Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(6 sites)

Germany

Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology, Berlin

Augenzentrum am St. Franziskus-Hospital Münster, Münster

Spain

Hospital Universitario Cruces, Bilbao

Fundación Jiménez Díaz, Madrid

United Kingdom

University of Bristol Bristol Medical School, Bristol

Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children NHS Foundation Trust, Sheffield